Brief: Morepen Laboratories Says Twin US FDA Approvals For Bulk Drugs Facilities
30/07/2018 04:33
July 30 (Reuters) - Morepen Laboratories Ltd MORL.NS :
* SAYS TWIN USFDA APPROVALS FOR MOREPEN LABS BULK DRUGS
(API)
FACILITIES
* BADDI FACILITY GETS US FDA NOD FOR BULK DRUG
"ATORVASTATIN" AND
MASULKHANA FACILITY FOR "MONTELUKAST"
Source text for Eikon: ID:nBSE2Rv5Vm
Further company coverage: MORL.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Morepen Laboratories
See all newsBrief: Morepen Laboratories Says High Court Quashes Notice Seeking Recovery Of 1.18 Billion Rupees
India's Morepen Laboratories gains on U.S. FDA submission for Sitagliptin tablets
Brief: Morepen Laboratories Submits First U.S. ANDA For Sitagliptin Tablets USP In Three Strengths
Brief: Morepen Laboratories Ltd June-Quarter Consol Net Profit 563.5 Million Rupees
India's Morepen Laboratories slips after quarterly profit fall